Guggenheim Upgrades Bristol-Myers Squibb Co. (BMY) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $61.48 -2.41%
Rating Summary:
11 Buy, 23 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
11 Buy, 23 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Guggenheim analyst Seamus Fernandez upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Neutral to Buy with a price target of $62.00.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $51.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phillip Securities Upgrades Indusind Bank Ltd (IIB:IN) to Buy
- Kotak Upgrades Indusind Bank Ltd (IIB:IN) to Reduce (3)
- Indusind Bank Ltd (IIB:IN) PT Lowered to INR875 at Axis Capital Limited
Create E-mail Alert Related Categories
UpgradesRelated Entities
Maynard Um, Guggenheim, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
